MELBOURNE, Australia, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Opthea Limited (ASX:OPT; NASDAQ:OPT), a clinical stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, announced that an oral presentation will be presented at the Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 conference, taking place from February 11-12, 2022.
Professor Gemmy Cheung will present data from patients with polypoidal choroidal vascul...
>>> Read more: Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference
Professor Gemmy Cheung will present data from patients with polypoidal choroidal vascul...
>>> Read more: Opthea Announces Presentation at the Angiogenesis, Exudation, and Degeneration 2022 Conference
